Man­u­fac­tur­ing roundup: Catal­ent to pro­duce low-cost ver­sion of nalox­one; CSL opens R&D site

Catal­ent will be man­u­fac­tur­ing a low-cost ver­sion of the opi­oid over­dose treat­ment nalox­one as part of a con­tract with Harm Re­duc­tion Ther­a­peu­tics.

Catal­ent plans to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER